NYSE: OSCROscar Health Inc Stock
$14.38-1.15 (-7.41%)
Updated Jul 11, 2025
OSCR Price
$14.38
Fair Value Price
N/A
Market Cap
$3.66B
52 Week Low
$11.20
52 Week High
$23.79
P/E
29.96x
P/B
2.75x
P/S
0.33x
PEG
1.89x
Dividend Yield
N/A
Revenue
$10.08B
Earnings
$123.34M
Gross Margin
20.3%
Operating Margin
1.65%
Profit Margin
1.2%
Debt to Equity
3.38
Operating Cash Flow
$1B
Beta
1.51
Next Earnings
Aug 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
OSCR Overview
Oscar Health, Inc. offers health insurance in the U.S., including individual & family, small mroup, and Medicare Advantage plans. Its +Oscar, a technology driven platform designed to help providers and payor engage with members and patients. The company also provides reinsurance products and services. Formerly Mulberry Health Inc., Oscar Health was incorporated in 2012 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OSCR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Plan
Industry Rating
A
OSCR
Ranked#10 of 10
Ranked#10 of 10
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $303.27 | A | |
| $64.78 | B | |
| $340.67 | B |
Be the first to know about important OSCR news, forecast changes, insider trades & much more!
OSCR News
Overview
Due Diligence Score
–
Industry Average (39)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OSCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OSCR ($14.38) is trading above its intrinsic value of $5.35, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OSCR is good value based on its earnings relative to its share price (29.96x), compared to the US market average (30.99x)
P/E vs Market Valuation
OSCR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more OSCR due diligence checks available for Premium users.
Valuation
OSCR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
29.96x
Industry
13.33x
Market
30.99x
OSCR is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
OSCR is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
OSCR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.75x
Industry
1.9x
OSCR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OSCR price to earnings growth (PEG)
For valuing profitable companies with growth potential
OSCR is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
OSCR's financial health
Profit margin
Revenue
$3.0B
Net Income
$275.3M
Profit Margin
9%
OSCR's Earnings (EBIT) of $166.18M... subscribe to Premium to read more.
Interest Coverage Financials
OSCR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.8B
Liabilities
$4.5B
Debt to equity
3.38
OSCR's short-term liabilities ($4.15B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OSCR's short-term assets ($3.77B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OSCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$878.5M
Investing
-$174.2M
Financing
$4.9M
OSCR's operating cash flow ($1.22B)... subscribe to Premium to read more.
Debt Coverage Financials
OSCR vs Healthcare Plan Stocks
Oscar Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.